

1, Csorvássy I., Tózsér L., **Kárpáti L.**, Náray-Szabó G.:

The molecular transform as a similarity measure.

*J. Mat. Chem.*, **13**(1), 343-357 (1993).

IF 1,295

2, Katona É., Haramura G., **Kárpáti L.**, Fachel J., Muszbek L.:

A simple, quick one-step ELISA assay for the determination of complex plasma factor XIII (A<sub>2</sub>B<sub>2</sub>).

*Thromb. Haemost.*, **83**(2), 268-273 (2000).

IF 4,372

3, Hevessy Z., Patthy A., **Kárpáti L.**, Muszbek L.:

$\alpha(2)$ -plasmin inhibitor is a substrate for tissue transglutaminase: an in vitro study.

*Thromb. Res.*, **99**(4), 399-406 (2000).

IF 1,323

4, Wartiovaara U., Mikkola H., Szőke G., Haramura G., **Kárpáti L.**, Balogh I., Lassila R., Muszbek L., Palotie A.:

Effect of Val34Leu polymorphism on the activation of the coagulation factor XIII-A.

*Thromb. Haemost.*, **84**(4), 595-600 (2000).

IF 4,372

5, Balogh I., Szőke G., **Kárpáti L.**, Wartiovaara U., Katona É., Komáromi I., Haramura G., Pfliegler G., Mikkola H., Muszbek L.:

Val34Leu polymorphism of plasma factor XIII: biochemistry and epidemiology in familial thrombophilia.

*Blood.*, **96**(7), 2479-2486 (2000).

IF 8,977

6, **Kárpáti L.**, Penke B., Katona É., Balogh I., Vámosi G., Muszbek L.:

A modified, optimized kinetic photometric assay for the determination of blood coagulation factor XIII activity in plasma.

*Clin. Chem.*, **46**(12), 1946-1955 (2000).

IF 4,261

7, Katona É., Ajzner É., Tóth K., **Kárpáti L.**, Muszbek L.:

Enzyme-linked immunosorbent assay for the determination of blood coagulation factor XIII A-subunit in plasma and in cell lysates.

*J Immunol. Methods.*, **258**(1-2), 127-135 (2001).

IF 2,283

8, Sárvári M., **Kárpáti L.**, Fésüs L., Deli L., Muszbek L., Nemes Z.:

Competitive enzyme-linked immunosorbent assay for N epsilon gamma-glutamyl lysine.

*Anal. Biochem.*, **311**(2), 187-190 (2002).

IF 2,370

9, Inbal A., Muszbek L., Lubetsky A., Katona É., Levi I., **Kárpáti L.**, Nagler A.:

Platelets but not monocytes contribute to the plasma levels of factor XIII subunit A in patients undergoing autologous peripheral blood stem cell transplantation.

*Blood. Coagul. Fibrinolysis.*, **15**(3), 249-253 (2004).

IF 1,506

10, Horváth A., Olive C., **Kárpáti L.**, Sun HK., Good M., Toth I.:

Toward the development of a synthetic group A streptococcal vaccine of high purity and broad protective coverage.

*J. Med. Chem.*, **47**(16), 4100-4104 (2004).

IF 5,076

11, Vehovszky Á., Agricola HJ., Elliott CJ., Ohtani M., **Kárpáti L.**, Hernádi L.:

Crustacean cardioactive peptide (CCAP)-related molluscan peptides (M-CCAPs) are potential extrinsic modulators of the buccal feeding network in the pond snail *Lymnaea stagnalis*.

*Neurosci. Lett.*, **373**(3), 200-205 (2004).

IF 2,019

12, Mádi A., **Kárpáti L.**, Kovács A., Muszbek L., Fésüs L.:

High-throughput scintillation proximity assay for transglutaminase activity measurement.

*Anal. Biochem.*, **343**(2), 256-262 (2005).

IF 2,670

13, Moyle PM., Horváth A., **Kárpáti L.**, Olive C., Barozzi N., Wimmer N., Good M., Toth I.:

Development of Peptide Vaccines against HPV-16 Associated Cervical Cancer and Group A Streptococci.

*Chapter in Biopolymers*, **80**, 407-408 (2006).

IF –

14, **Kárpáti L.**, Komáromi I.:

Monitoring the oxidation of decapeptide (S) Q-E-C-K-D-G(R)-E-C-P-W - derived from the sequence of blood coagulation factor X - by reversed-phase HPLC.

*Journal of Peptide Science*, **12**, 110-110 (2006).

IF 1,801

15, Toth I., Moyle PM., **Kárpáti L.**, Horvath A., Olive C., Good FM.:

The lipid core peptide system in vaccine delivery.

*International Congress Series*, Apr , 307-310 (2006).

IF 2,5

16, Moyle PM., **Kárpáti L.**, Burgess M., Good M., Olive C., Ho MF., Toth I.:

Towards the synthesis of a highly pure, multiepitopic, mucosal group A streptococcal lipopeptide vaccine.

*International Congress Series*, Apr, 324-328 (2006).

IF 2,5

17, Moyle PM., Olive C., **Kárpáti L.**, Barozzi N., Good M., Dyer J., Sun KH., Ho MF., Toth I.:

Synthesis and Immunological Evaluation of M Protein Targeted Tetra-Valent and Tri-Valent Group A Streptococcal Vaccine Candidates Based on the Lipid-Core Peptide System.

*International Journal of Peptide Research and Therapeutics*, **12**(3), 317-326 (2006).

IF 0,536

18, Moyle PM, Olive C, Ho MF, Burgess M, **Kárpáti L**, Good MF, Toth I.

Method for the synthesis of multi-epitopic *Streptococcus pyogenes* lipopeptide vaccines using native chemical ligation.

*J. Org. Chem.*, **71**(18), 6846-6850 (2006).

IF 3,790

19, Bereczky Z., Balogh E., Katona É., Pocsai Z., Czuriga I., Széles G., **Kárpáti L.**, Ádány R., Édes I., Muszbek L.:

Modulation of the risk of coronary sclerosis/myocardial infarction by the interaction between factor XIII subunit A Val34Leu polymorphism and fibrinogen concentration in the high risk Hungarian population.

*Thromb. Res.*, **120**(4), 567-573 (2007).

IF 2,038

20, Bereczky Z., Balogh E., Katona É., **Kárpáti L.**, Czuriga I., Édes I., Muszbek L.:

Elevated Factor XIII level is associated with an increased risk of myocardial infarction in women.

*Journal of Thrombosis and Haemostasis*, **5** P-M-581-P-M-581, July (2007).

IF 3,501

21, Bereczky Z., Balogh E., Katona É., **Kárpáti L.**, Czuriga I., Édes I., Muszbek L.:  
Elevated factor XIII level represents an increased risk of myocardial infarction in women.  
*Thromb. Res.*, **119**, S99–S100 (2007).

IF 2,038

22, Bereczky Z., Balogh E., Katona É., Czuriga I., **Kárpáti L.**, Shemirani AH., Édes I.,  
Muszbek L.:  
Decreased factor XIII levels in factor XIII A subunit Leu34 homozygous patients with  
coronary artery disease.

*Thromb Res.*, **121**(4), 469-476 (2008).

IF 2,449

23, Hernádi L., **Kárpáti L.**, Győri J., Vehovszky Á., Hiripi L.:  
Humoral serotonin and dopamine modulate the feeding in the snail, *Helix pomatia*.  
*Acta. Biol. Hung.*, **59**, Suppl:39-46 (2008).

IF 0,619

24, Trencsényi G., Kertész I., Krasznai ZT., Máté G., Szalóki G., Szabó Judit P., **Kárpáti L.**,  
Krasznai Z., Márián T., Goda K.:  
2'[(18)F]-fluoroethylrhodamine B is a promising radiotracer to measure P-glycoprotein  
function.

*Eur. J. Pharm. Sci.*, **74**, 27-35 (2015).

IF 3,350

25, Balogh I., Katona É., **Kárpáti L.**, Pfliegler G., Muszbek L:

Factor XIII Val34Leu polymorphism: Frequency in familial thrombophilia patients and the lack of its effect on plasma FXIII level and activity.

*FIBRINOLYSIS & PROTEOLYSIS*, **14**, (SUPPL. 1) p.80 (2000).

IF 1,354

26, Muszbek L., Katona É., Bereczky Z., Balogh E., Czuriga I., **Kárpáti L.**, Édes I.:

Factor Xiii Levels And Factor Xiii A Subunit Val34leu Polymorphism in Patients With Coronary Sclerosis And Myocardial Infarction.

*CLINICA CHIMICA ACTA*, **355**, p.S94 (2005).

IF 2,149

Total IF 69,149.

Citáció: 521.